Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 11/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11359525 | 0.86 | SIGMAR1 (0.56) | SIGMAR1OPRM1KCNH2SSTR5DRD2 | |
| SCHEMBL24993849 | 0.79 | OPRM1 (0.65) | SIGMAR1OPRM1SSTR5 | |
| SCHEMBL3222232 | 0.78 | SIGMAR1 (0.71) | SIGMAR1OPRM1KCNH2SSTR5 | |
| SCHEMBL11367088 | 0.77 | SIGMAR1 (0.56) | SIGMAR1OPRM1KCNH2DRD2 | |
| SCHEMBL735835 | 0.77 | NPY5R (0.47) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL17319083 | 0.77 | SIGMAR1 (0.66) | SIGMAR1OPRM1KCNH2DRD2 | |
| SCHEMBL11368838 | 0.75 | SIGMAR1 (0.52) | SIGMAR1OPRM1KCNH2DRD2TACR2 | |
| SCHEMBL14963497 | 0.75 | OPRM1 (0.54) | SIGMAR1OPRM1SSTR5 | |
| SCHEMBL3031924 | 0.75 | NPY5R (0.48) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL3741390 | 0.75 | NPY5R (0.52) | SIGMAR1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009037542-A2 | SPIROCYCLIC COMPOUNDS AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-03-26 | — | — | WO | disclosed |